Premium
P1‐451: Mid‐life dementia risk scores as a predictor of CSF biomarker response to simvastatin therapy in asymptomatic adults at risk for Alzheimer's disease: The ESPRIT study
Author(s) -
Marsh Alyce J.,
Barnet Jodi H.,
Blazel Hanna M.,
Gleason Carey E.,
Johnson Sterling C.,
Zetterberg Henrik,
Blennow Kaj,
Hermann Bruce P.,
Dowling N. Maritza,
Puglielli Luigi,
Atwood Craig S.,
Sager Mark A.,
Asthana Sanjay,
Carlsson Cynthia M.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1007
Subject(s) - medicine , dementia , biomarker , simvastatin , framingham risk score , disease , oncology , physical therapy , biochemistry , chemistry
P1-451 MID-LIFE DEMENTIA RISK SCORES AS A PREDICTOR OF CSF BIOMARKER RESPONSE TO SIMVASTATIN THERAPY IN ASYMPTOMATIC ADULTS AT RISK FOR ALZHEIMER’S DISEASE: THE ESPRIT STUDY Alyce J. Marsh, Jodi H. Barnet, Hanna M. Blazel, Carey E. Gleason, Sterling C. Johnson, Henrik Zetterberg, Kaj Blennow, Bruce P. Hermann, N. Maritza Dowling, Luigi Puglielli, Craig S. Atwood, Mark A. Sager, Sanjay Asthana, Cynthia M. Carlsson, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer’s Disease Research Center (ADRC), Madison, WI, USA; Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden. Contact e-mail: ajmarsh@ medicine.wisc.edu